Kalender
| Est. tid* | ||
| 2027-02-17 | 08:30 | Bokslutskommuniké 2026 |
| 2026-11-18 | 08:30 | Kvartalsrapport 2026-Q3 |
| 2026-08-19 | 08:30 | Kvartalsrapport 2026-Q2 |
| 2026-05-20 | 08:30 | Kvartalsrapport 2026-Q1 |
| 2026-02-18 | 08:30 | Bokslutskommuniké 2025 |
| 2025-12-02 | - | Extra Bolagsstämma 2025 |
| 2025-11-19 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-21 | - | Kvartalsrapport 2025-Q1 |
| 2025-05-09 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2025-04-08 | - | Årsstämma |
| 2025-02-19 | - | Bokslutskommuniké 2024 |
| 2024-11-20 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-05 | - | Årsstämma |
| 2024-05-23 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2024-05-22 | - | Kvartalsrapport 2024-Q1 |
| 2024-03-04 | - | Extra Bolagsstämma 2023 |
| 2024-02-21 | - | Bokslutskommuniké 2023 |
| 2023-11-22 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-30 | - | Årsstämma |
| 2023-05-31 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-25 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2023-02-15 | - | Bokslutskommuniké 2022 |
| 2022-12-23 | - | Extra Bolagsstämma 2022 |
| 2022-11-16 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-17 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-19 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2022-05-18 | - | Årsstämma |
| 2022-05-18 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-11-10 | - | Kvartalsrapport 2021-Q3 |
| 2021-11-03 | - | Extra Bolagsstämma 2021 |
| 2021-08-11 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-23 | - | Årsstämma |
| 2021-05-20 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2021-05-19 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-17 | - | Bokslutskommuniké 2020 |
| 2020-11-11 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-12 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-29 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2020-06-26 | - | Årsstämma |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-20 | - | Bokslutskommuniké 2019 |
| 2019-11-13 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-14 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-27 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2019-05-24 | - | Årsstämma |
| 2019-05-24 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-21 | - | Bokslutskommuniké 2018 |
| 2018-11-07 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-15 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-17 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2018-05-16 | - | Årsstämma |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-15 | - | Bokslutskommuniké 2017 |
| 2017-11-15 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-16 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-18 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2017-05-17 | - | Årsstämma |
| 2017-05-17 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-15 | - | Bokslutskommuniké 2016 |
| 2016-10-27 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-29 | - | Kvartalsrapport 2016-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Enorama Pharma AB (publ) ("Enorama Pharma" or the "Company") today announces that the board of directors has decided to postpone the publication of the Company's 2025 year-end report until 11 March 2026. The previously announced date for publication of the year-end report was 17 February 2026.
The postponement of the publication of the year-end report is due to the Refuse-to-File decision from the U.S. Food and Drug Administration, as previously announced by Enorama Pharma on 2 February 2026, and the need to prepare a balance sheet for liquidation purposes.
CONTACT
Enorama Pharma AB (publ)
Bengt Jönsson, acting CEO
[email protected]
Strandvägen 7A, 114 51 Stockholm.
www.enorama.se
Enorama Pharma AB is listed on Nasdaq First North Growth Market.
The company's Certified Adviser is Tapper Partners AB, +46 (0)70 44 010 98, [email protected].
ABOUT ENORAMA PHARMA
Enorama Pharma's vision is to be a leading global producer and supplier of consumer-friendly, oral nicotine products. The company intends to expand through product and brand development and by establishing strategically important collaborations. For more information, visit www.enorama.se.